| abstract |
The use of 1-MNA or a pharmaceutically acceptable salt thereof to reduce the risk of cardiovascular disease in a subject with a serum or blood CRP level of less than 10 mg / L. The description also describes the use of 1-MNA or a pharmaceutically acceptable salt thereof in the amount effective to reduce the level of CRP in serum or blood for the treatment of diseases such as rheumatoid arthritis, colon cancer, breast cancer, cancer. lung disease, infection, inflammatory bowel disease, lupus erythematosus, pneumococcal pneumonia, rheumatic fever, tuberculosis, kidney failure, amyotrophic lateral sclerosis, or a combination of these. |